A Randomized Trial of Nafamostat for Covid-19

Overview of attention for article published in NEJM Evidence, October 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter: 18 X users

Readers on

mendeley: 28 Mendeley

So far, Altmetric has seen 21 X posts from 18 X users, with an upper bound of 114,183 followers.

Among hospitalized patients with Covid-19, there was a 93% posterior probability that nafamostat reduced the odds of death or organ support. Hyperkalemia and bleeding were more common with nafamostat. Oct 18, 2023 https://t.co/Fm1P2h9bmo

"Among hospitalized patients with Covid-19, there was a 93% posterior probability that nafamostat reduced the odds of death or organ support." https://t.co/xIOvzdA17r

A Randomized Trial of Nafamostat for Covid-19 https://t.co/JGFVhn0Lt0

RT @RVarmaMD: Probably no conflicts of interest but these paragraphs are getting as long as the discussion part. See and comment. A Rando…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 17 additional X posts.